MX2009006744A - Cardiovascular autoimmune disease panel and methods of using same. - Google Patents

Cardiovascular autoimmune disease panel and methods of using same.

Info

Publication number
MX2009006744A
MX2009006744A MX2009006744A MX2009006744A MX2009006744A MX 2009006744 A MX2009006744 A MX 2009006744A MX 2009006744 A MX2009006744 A MX 2009006744A MX 2009006744 A MX2009006744 A MX 2009006744A MX 2009006744 A MX2009006744 A MX 2009006744A
Authority
MX
Mexico
Prior art keywords
cardiovascular
autoimmune disease
methods
disease
risk
Prior art date
Application number
MX2009006744A
Other languages
Spanish (es)
Inventor
Robert C Doss
Phillip G Mattingly
Roy Jeffrey Brashear
Maciej B Adamczyk
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2009006744A publication Critical patent/MX2009006744A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Abstract

Provided herein among other things are diagnostic tests, methods of use, and kits for the assessment and management of cardiovascular autoimmune disease and risk of cardiovascular autoimmune disease. Assay methods of the invention can be employed among other things to identify cardiovascular autoimmune disease, or risk thereof, in subjects who have cardiovascular disease, an autoimmune disease, or who are related to an individual with an autoimmune disease. The method can be employed for testing of a subject that exhibits symptoms of cardiovascular disease, as well as of a subject that is apparently healthy and does not yet exhibit symptoms of cardiovascular disease, but may with time. In one embodiment, the invention also provides a method of determining whether a subject having, or at risk for, a cardiovascular disease is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.
MX2009006744A 2006-12-22 2007-12-21 Cardiovascular autoimmune disease panel and methods of using same. MX2009006744A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87660306P 2006-12-22 2006-12-22
PCT/US2007/088477 WO2008080030A2 (en) 2006-12-22 2007-12-21 Cardiovascular autoimmune disease panel and methods of using same

Publications (1)

Publication Number Publication Date
MX2009006744A true MX2009006744A (en) 2009-06-30

Family

ID=39563225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006744A MX2009006744A (en) 2006-12-22 2007-12-21 Cardiovascular autoimmune disease panel and methods of using same.

Country Status (6)

Country Link
EP (1) EP2115466A4 (en)
JP (1) JP2010515023A (en)
BR (1) BRPI0720215A2 (en)
CA (1) CA2669863A1 (en)
MX (1) MX2009006744A (en)
WO (1) WO2008080030A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097750A2 (en) 2006-10-26 2009-09-09 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
EP2148203A1 (en) * 2008-07-23 2010-01-27 BRAHMS Aktiengesellschaft Azurophilic granule proteases as markers in cardiological diseases
US20110136141A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
EP2580593A4 (en) * 2010-06-10 2014-04-16 Myra Lipes Diagnosis of myocardial autoimmunity in heart disease
EP3347721B1 (en) 2015-09-09 2020-06-10 Medizinische Hochschule Hannover Diagnosing and treating peripartum cardiomyopathy through the level of plasminogen activator inhibitor
CN112858687B (en) * 2020-12-30 2023-09-15 宁波职业技术学院 Serum amyloid A detection reagent and preparation method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
SE0103754L (en) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptides from apolipoprotein B, use thereof immunization, method of diagnosis or therapeutic treatment of ischemic cardiovascular diseases, and pharmaceutical composition and vaccine containing such peptide
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20030100036A1 (en) * 2001-11-08 2003-05-29 Aristo Vojdani Saliva immunoassay for detection of antibodies for cardiovascular disease
DE602004030898D1 (en) * 2003-04-16 2011-02-17 Tasuku Honjo SCREENING METHOD FOR REMEDIES FOR HEART DISEASE AND MEDICAL COMPOSITION FOR THE TREATMENT OF HEART DISEASE
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
PT1735349E (en) * 2004-04-15 2010-12-14 Athera Biotechnologies Ab Method of assessing the risk of ischemic cardiovascular disease using phosphorylcholine conjugates
JP5350779B2 (en) * 2005-03-31 2013-11-27 ユリウス−マクシミリアンズ−ユニバーシタット ブルツブルグ Means for inhibiting anti-β1 adrenergic receptor antibodies
WO2007085411A1 (en) * 2006-01-25 2007-08-02 Roche Diagnostics Gmbh Anti-troponin antibodies and cardiovascular risk
EP2047263A4 (en) * 2006-07-26 2009-11-18 Inova Diagnostics Inc Compositions and methods for diagnosing patients with acute atherosclerotic syndromes

Also Published As

Publication number Publication date
WO2008080030A2 (en) 2008-07-03
WO2008080030A3 (en) 2008-10-09
JP2010515023A (en) 2010-05-06
EP2115466A4 (en) 2010-07-28
CA2669863A1 (en) 2008-07-03
EP2115466A2 (en) 2009-11-11
BRPI0720215A2 (en) 2013-12-24

Similar Documents

Publication Publication Date Title
MX2009004463A (en) Assay for cardiac troponin autoantibodies.
Schwid et al. Cognitive fatigue during a test requiring sustained attention: a pilot study
MX2009006744A (en) Cardiovascular autoimmune disease panel and methods of using same.
Thorsen et al. Reliability of the Copenhagen psychosocial questionnaire
Lurz et al. Frailty in children with liver disease: a prospective multicenter study
WO2009092386A3 (en) A new method to measure and characterize microvesicles in the human body fluids
EP2319941A3 (en) Method and apparatus for correlating levels of biomarker products with disease
EP1718768A4 (en) Methods and compositions for determining a graft tolerant phenotype in a subject
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
MX2012007009A (en) Method for diagnosing malignant tumor.
BRPI0512948A (en) biomarkers of alzheimer's disease
BRPI0722361B8 (en) Methods for Assessing the Concentration of an Immunosuppressive Drug in a Human Blood Sample, Extraction Reagent Composition, and Test Kit
ATE550668T1 (en) METHOD FOR IDENTIFYING PATIENTS AT INCREASED RISK OF AN ADVERSE CARDIOVASCULAR EVENT
DE502004005226D1 (en) DIAGNOSIS OF ACUTE MYOCARDIALS, ISCHEMIC ILLNESSES BY COMBINATION OF MARKERS
IN2014DN08537A (en)
MX2009001070A (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma.
BR112015021507A8 (en) Methods and Compositions for the Diagnosis of Preeclampsia in a Pregnant Woman and Diagnostic Test Kit
Kovacs et al. Independent validation of the quality of life in essential tremor questionnaire (QUEST)
NZ540750A (en) Sets of oligonucleotide probes for diagnosis
ATE503847T1 (en) METHODS AND KITS FOR DIAGNOSING MULTIPLE SCLERosis IN PROBABLY MULTIPLE SCLEROSIS PATIENTS
Gençöz et al. Hopelessness and suicidality in Turkish and American respondents
Munteanu Non-invasive biomarkers FibroTest-ActiTest for replacing invasive liver biopsy: the need for change and action
ME01128B (en) Use of 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels
Andreas et al. Does a more specified version of the Honos (Health of the Nation Outcome Scales) increase psychometric properties of the inventory?

Legal Events

Date Code Title Description
FG Grant or registration